convalescent plasma treatment - versus control - for COVID-19 pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 0.97 [0.74, 1.27]< 19%16 studies (16/-)58.3 %some concernlow moderatecrucial-
deaths 0.98 [0.92, 1.04]< 10%28 studies (28/-)71.4 %some concerncritical moderatecrucial-
deaths (time to event analysis only) 0.90 [0.63, 1.28]< 125%3 studies (3/-)72.4 %some concernnot evaluable moderatecrucial-
hospitalization or death 0.91 [0.63, 1.33]< 10%1 study (1/-)68.1 %some concernnot evaluable moderatecrucial-
clinical deterioration 0.77 [0.55, 1.07]< 113%4 studies (4/-)93.9 %some concernnot evaluable moderateimportant-
clinical improvement 1.03 [0.88, 1.21]> 10%6 studies (6/-)65.9 %some concernnot evaluable moderateimportant-
clinical improvement (14-day) 2.27 [0.90, 5.72]> 10%1 study (1/-)95.9 %some concernnot evaluable moderateimportant-
clinical improvement (28-day) 1.01 [0.82, 1.26]> 10%3 studies (3/-)54.9 %some concernnot evaluable moderateimportant-
clinical improvement (7-day) 0.98 [0.27, 3.58]> 10%1 study (1/-)48.8 %some concernnot evaluable moderateimportant-
clinical improvement (time to event analysis only) 1.09 [0.91, 1.30]> 10%4 studies (4/-)82.4 %some concernnot evaluable moderateimportant-
death or ventilation 0.99 [0.92, 1.06]< 143%3 studies (3/-)63.7 %some concernnot evaluable moderateimportant-
hospital discharge 0.99 [0.92, 1.07]> 10%2 studies (2/-)44.3 %some concernnot evaluable moderateimportant-
hospitalization 0.88 [0.57, 1.34]< 10%1 study (1/-)73.0 %some concernnot evaluable moderateimportant-
mechanical ventilation 0.98 [0.89, 1.08]< 10%5 studies (5/-)65.8 %some concernnot evaluable moderateimportant-
viral clearance by day 14 0.95 [0.76, 1.19]> 10%1 study (1/-)32.7 %some concernnot evaluable moderateimportant-
viral clearance by day 7 0.87 [0.65, 1.16]> 10%1 study (1/-)17.3 %some concernnot evaluable moderateimportant-
ICU admission 0.33 [0.07, 1.58]< 10%1 study (1/-)91.7 %lownot evaluable highnon important-

safety endpoints 00

serious adverse events 1.19 [0.94, 1.50]< 145%6 studies (6/-)7.8 %some concernnot evaluable moderateimportant-
adverse events 1.08 [0.86, 1.37]< 10%2 studies (2/-)24.8 %some concernnot evaluable moderatenon important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.